EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube
News archive
Recent news

MPE is very proud to have been accepted as member of the Patients’ and Consumers’ Working Party (PCWP) at the European Medicines Agency for the term 2016-2019.

The PCWP provides a platform for exchange of information and discussion of issues of common interest between the EMA and patients and consumers. It was established in 2006, and has enabled the Agency to build upon its existing interactions with patients and consumers. It provides recommendations to the EMA and its human scientific committees on all matters of interest in relation to medicines.

MPE and its members have been working intensively over the last couple of years to move from anecdotal reporting to evidence based advocacy. The most recent example is the development of the European Atlas of Access to Myeloma Treatment, which is about to be launched. We will continue to develop solid evidence on the needs and wants of myeloma patients across Europe, and work hard to ensure these are taken into account by the regulator.

You can find more information on the PCWP here http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000708.jsp&mid=WC0b01ac0580028d32







Recent news

» Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosis

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.